A nonhuman primate model for human cerebral malaria

Effects of artesunate (qinghaosu derivative) on rhesus monkeys experimentally infected with Plasmodium coatneyi

Y. Maeno, A. E. Brown, C. D. Smith, T. Tegoshi, T. Toyoshima, C. F. Ockenhouse, K. D. Corcoran, M. Ngampochjana, D. E. Kyle, H. K. Vebster, M. Aikawa

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We studied the effects of artesunate on rhesus monkeys infected with Plasmodium coatneyi. Sixteen rhesus monkeys were divided in four groups. Group I consisted of three monkeys that were splenectomized and were treated with three doses (loading dose: 3.3 mg/kg, maintenance doses: 1.7 mg/kg) of artesunate, group II consisted of three monkeys that were treated with three doses of artesunate (same as group I), group III consisted of two monkeys that were treated with one dose (3.3 mg/kg) of artesunate, and group IV consisted of five untreated monkeys. Parasitemias of these groups ranged from 13.3% to 19.5% before treatment. Twenty-four hours after administration, the parasitemia was reduced to 2.2% in group I and to < 0.1% in group II; parasitemia was lowered to 10.6% in group III only 3 hr after drug administration. The rate of sequestration in the cerebral microvessels, which was 29.4% in untreated animals, was < 0.1% in groups I and II (24 hr after treatment), and 2.0% in group III (3 hr after treatment). These data clearly indicate that artesunate not only reduced parasitemia, but also reduced the rate of parasitized red blood cell (PRBC) sequestration in cerebral microvessels. In an immunohistologic study, endothelial-leukocyte adhesion molecule-1 (ELAM-1) was not detected in group I after treatment with artesunate, although the presence of CD36, thrombospondin, intercellular adhesion molecule-1. IgG, and C3 in the cerebral microvessels was not altered. This is the first in vivo study to show that artesunate interferes with continued PRBC sequestration in the cerebral microvessels in cerebral malaria. By using this animal model, we may be able to evaluate strategies for management of severe malaria as well as for the development of antimalarials and vaccines to prevent and/or cure cerebral malaria.

Original languageEnglish
Pages (from-to)726-734
Number of pages9
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume49
Issue number6
DOIs
Publication statusPublished - 01-01-1993
Externally publishedYes

Fingerprint

Cerebral Malaria
Plasmodium
Macaca mulatta
Primates
Parasitemia
Microvessels
Haplorhini
Erythrocytes
Thrombospondins
E-Selectin
Antimalarials
Intercellular Adhesion Molecule-1
artesunate
artemisinine
Malaria
Vaccines
Animal Models
Immunoglobulin G
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Parasitology
  • Infectious Diseases
  • Virology

Cite this

Maeno, Y. ; Brown, A. E. ; Smith, C. D. ; Tegoshi, T. ; Toyoshima, T. ; Ockenhouse, C. F. ; Corcoran, K. D. ; Ngampochjana, M. ; Kyle, D. E. ; Vebster, H. K. ; Aikawa, M. / A nonhuman primate model for human cerebral malaria : Effects of artesunate (qinghaosu derivative) on rhesus monkeys experimentally infected with Plasmodium coatneyi. In: American Journal of Tropical Medicine and Hygiene. 1993 ; Vol. 49, No. 6. pp. 726-734.
@article{f49e444d78cb46db85998f37f67d66d0,
title = "A nonhuman primate model for human cerebral malaria: Effects of artesunate (qinghaosu derivative) on rhesus monkeys experimentally infected with Plasmodium coatneyi",
abstract = "We studied the effects of artesunate on rhesus monkeys infected with Plasmodium coatneyi. Sixteen rhesus monkeys were divided in four groups. Group I consisted of three monkeys that were splenectomized and were treated with three doses (loading dose: 3.3 mg/kg, maintenance doses: 1.7 mg/kg) of artesunate, group II consisted of three monkeys that were treated with three doses of artesunate (same as group I), group III consisted of two monkeys that were treated with one dose (3.3 mg/kg) of artesunate, and group IV consisted of five untreated monkeys. Parasitemias of these groups ranged from 13.3{\%} to 19.5{\%} before treatment. Twenty-four hours after administration, the parasitemia was reduced to 2.2{\%} in group I and to < 0.1{\%} in group II; parasitemia was lowered to 10.6{\%} in group III only 3 hr after drug administration. The rate of sequestration in the cerebral microvessels, which was 29.4{\%} in untreated animals, was < 0.1{\%} in groups I and II (24 hr after treatment), and 2.0{\%} in group III (3 hr after treatment). These data clearly indicate that artesunate not only reduced parasitemia, but also reduced the rate of parasitized red blood cell (PRBC) sequestration in cerebral microvessels. In an immunohistologic study, endothelial-leukocyte adhesion molecule-1 (ELAM-1) was not detected in group I after treatment with artesunate, although the presence of CD36, thrombospondin, intercellular adhesion molecule-1. IgG, and C3 in the cerebral microvessels was not altered. This is the first in vivo study to show that artesunate interferes with continued PRBC sequestration in the cerebral microvessels in cerebral malaria. By using this animal model, we may be able to evaluate strategies for management of severe malaria as well as for the development of antimalarials and vaccines to prevent and/or cure cerebral malaria.",
author = "Y. Maeno and Brown, {A. E.} and Smith, {C. D.} and T. Tegoshi and T. Toyoshima and Ockenhouse, {C. F.} and Corcoran, {K. D.} and M. Ngampochjana and Kyle, {D. E.} and Vebster, {H. K.} and M. Aikawa",
year = "1993",
month = "1",
day = "1",
doi = "10.4269/ajtmh.1993.49.726",
language = "English",
volume = "49",
pages = "726--734",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "6",

}

A nonhuman primate model for human cerebral malaria : Effects of artesunate (qinghaosu derivative) on rhesus monkeys experimentally infected with Plasmodium coatneyi. / Maeno, Y.; Brown, A. E.; Smith, C. D.; Tegoshi, T.; Toyoshima, T.; Ockenhouse, C. F.; Corcoran, K. D.; Ngampochjana, M.; Kyle, D. E.; Vebster, H. K.; Aikawa, M.

In: American Journal of Tropical Medicine and Hygiene, Vol. 49, No. 6, 01.01.1993, p. 726-734.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A nonhuman primate model for human cerebral malaria

T2 - Effects of artesunate (qinghaosu derivative) on rhesus monkeys experimentally infected with Plasmodium coatneyi

AU - Maeno, Y.

AU - Brown, A. E.

AU - Smith, C. D.

AU - Tegoshi, T.

AU - Toyoshima, T.

AU - Ockenhouse, C. F.

AU - Corcoran, K. D.

AU - Ngampochjana, M.

AU - Kyle, D. E.

AU - Vebster, H. K.

AU - Aikawa, M.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - We studied the effects of artesunate on rhesus monkeys infected with Plasmodium coatneyi. Sixteen rhesus monkeys were divided in four groups. Group I consisted of three monkeys that were splenectomized and were treated with three doses (loading dose: 3.3 mg/kg, maintenance doses: 1.7 mg/kg) of artesunate, group II consisted of three monkeys that were treated with three doses of artesunate (same as group I), group III consisted of two monkeys that were treated with one dose (3.3 mg/kg) of artesunate, and group IV consisted of five untreated monkeys. Parasitemias of these groups ranged from 13.3% to 19.5% before treatment. Twenty-four hours after administration, the parasitemia was reduced to 2.2% in group I and to < 0.1% in group II; parasitemia was lowered to 10.6% in group III only 3 hr after drug administration. The rate of sequestration in the cerebral microvessels, which was 29.4% in untreated animals, was < 0.1% in groups I and II (24 hr after treatment), and 2.0% in group III (3 hr after treatment). These data clearly indicate that artesunate not only reduced parasitemia, but also reduced the rate of parasitized red blood cell (PRBC) sequestration in cerebral microvessels. In an immunohistologic study, endothelial-leukocyte adhesion molecule-1 (ELAM-1) was not detected in group I after treatment with artesunate, although the presence of CD36, thrombospondin, intercellular adhesion molecule-1. IgG, and C3 in the cerebral microvessels was not altered. This is the first in vivo study to show that artesunate interferes with continued PRBC sequestration in the cerebral microvessels in cerebral malaria. By using this animal model, we may be able to evaluate strategies for management of severe malaria as well as for the development of antimalarials and vaccines to prevent and/or cure cerebral malaria.

AB - We studied the effects of artesunate on rhesus monkeys infected with Plasmodium coatneyi. Sixteen rhesus monkeys were divided in four groups. Group I consisted of three monkeys that were splenectomized and were treated with three doses (loading dose: 3.3 mg/kg, maintenance doses: 1.7 mg/kg) of artesunate, group II consisted of three monkeys that were treated with three doses of artesunate (same as group I), group III consisted of two monkeys that were treated with one dose (3.3 mg/kg) of artesunate, and group IV consisted of five untreated monkeys. Parasitemias of these groups ranged from 13.3% to 19.5% before treatment. Twenty-four hours after administration, the parasitemia was reduced to 2.2% in group I and to < 0.1% in group II; parasitemia was lowered to 10.6% in group III only 3 hr after drug administration. The rate of sequestration in the cerebral microvessels, which was 29.4% in untreated animals, was < 0.1% in groups I and II (24 hr after treatment), and 2.0% in group III (3 hr after treatment). These data clearly indicate that artesunate not only reduced parasitemia, but also reduced the rate of parasitized red blood cell (PRBC) sequestration in cerebral microvessels. In an immunohistologic study, endothelial-leukocyte adhesion molecule-1 (ELAM-1) was not detected in group I after treatment with artesunate, although the presence of CD36, thrombospondin, intercellular adhesion molecule-1. IgG, and C3 in the cerebral microvessels was not altered. This is the first in vivo study to show that artesunate interferes with continued PRBC sequestration in the cerebral microvessels in cerebral malaria. By using this animal model, we may be able to evaluate strategies for management of severe malaria as well as for the development of antimalarials and vaccines to prevent and/or cure cerebral malaria.

UR - http://www.scopus.com/inward/record.url?scp=0027730697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027730697&partnerID=8YFLogxK

U2 - 10.4269/ajtmh.1993.49.726

DO - 10.4269/ajtmh.1993.49.726

M3 - Article

VL - 49

SP - 726

EP - 734

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 6

ER -